USA flag logo/image

An Official Website of the United States Government

Recombinant human serum albumin for use in cell culture media

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
85683
Program Year/Program:
2007 / SBIR
Agency Tracking Number:
GM079828
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
VENTRIA BIOSCIENCE
320 East Vine Drive FORT COLLINS, CO -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2007
Title: Recombinant human serum albumin for use in cell culture media
Agency: HHS
Contract: 1R43GM079828-01
Award Amount: $99,982.00
 

Abstract:

DESCRIPTION (provided by applicant): Plasma-derived human serum albumin (pHSA) or bovine serum albumin are commonly added to cell culture media used in cell culture-based vaccine and therapeutic production, because it enhances cell growth and increases pr otein productivity. However, the use of pHSA carries the risk of transmission of virus and emerging infectious pathogens, such as prions, from blood for which no tests are available. In addition, existing heat treatments for blood and blood products are in effective for prions and possibly unidentified infectious agents. Because millions of people are immunized annually with cell culture-based vaccines and millions more require cell culture-based therapeutics for the treatment of various disorders, regulator y agencies have called for the replacement of pHSA in vaccine and therapeutic production with recombinant HSA (rHSA). In this Phase I proposal, the goal is to test the effectiveness of rice-derived rHSA compared to pHSA as an ingredient in cell culture med ia. Growth studies will be performed on Vero, hybridoma AE1, and Chinese hamster ovary (CHO) cells cultured in serum- free cell culture media supplemented with rHSA. Determination of cell mass, growth rate, and viability on all three cell lines will be mea sured. In addition, monoclonal antibody production by AE1 and CHO cells will be quantitatively measured using IgG-specific enzyme linked immunosorbent assays. The similarity of growth, development, and protein productivity of cells cultured in rHSA supplem ented cell culture media to pHSA supplemented media will lead us to scale-up in Phase II, which will be to determine the growth of cells in the presence of rHSA in bioreactors and assess the ability of cells to produce vaccines. If successful, our project will have addressed the call by agencies for a safe alternative to pHSA and animal blood products in vaccine and therapeutic production. Safety concerns regarding human-to-human transmission of emerging infectious pathogens from the use of plasma-derived h uman serum albumin (pHSA) and blood products as an ingredient in cell culture media for cell-based vaccine and therapeutic production exist. Regulatory agencies have called for the replacement of pHSA with recombinant HSA. In response, an inexpensive sourc e of recombinant HSA produced in rice would not only assure a safe alternative to pHSA, but would also allow cost- effective production of cell-based vaccine and therapeutics.

Principal Investigator:

Ning Huang
9169216148
NHUANG@VENTRIA.COM

Business Contact:

Ning Huang
Small Business Information at Submission:

VENTRIA BIOSCIENCE
VENTRIA BIOSCIENCE 4110 N FREEWAY BLVD SACRAMENTO, CA 95834

EIN/Tax ID: 680310843
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No